Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Terminated 1Completed 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 6Breast 5Thoracic 3Gynecologic 3Sarcoma 2Genitourinary 2Dermatologic 2Tumor-Agnostic 1Plasma cell 1Other solid neoplasm 1Other hematologic neoplasm 1Head & Neck 1

Conditions

Uveal Melanoma 1Neoplasm Metastasis 1Melanoma 1

Interventions

Nivolumab 168Ipilimumab 152pembrolizumab 143Cyclophosphamide 126Interleukin-2 70aldesleukin 69fludarabine phosphate 68Radiotherapy 67Biopsy 53Temozolomide 48Blood Specimen Collection 45Peripheral Blood Stem Cell Transplantation 44fludarabine 43Radiosurgery 40trametinib 38Vemurafenib 36dabrafenib 33sargramostim 32Bevacizumab 31Aminolevulinic Acid 31Magnetic Resonance Spectroscopy 30Mycophenolic Acid 29Specimen Handling 28Whole-Body Irradiation 27Photochemotherapy 26Imiquimod 26CTLA-4 Antigen 26Busulfan 26Tacrolimus 25Surveys and Questionnaires 25

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
OTHER × STA 9090 × Dermatologic × Clear all
NCT01200238 2018-10-18

STA-9090(Ganetespib) in Metastatic Ocular Melanoma

Dana-Farber Cancer Institute

Phase 2 Completed
17 enrolled 12 charts
Dermatologic

Uveal Melanoma

NCT01551693 2017-04-12

STA-9090(Ganetespib) in Patients With Unresectable Stage III or Stage IV Melanoma

Dana-Farber Cancer Institute

Phase 2 Terminated
3 enrolled 7 charts
Dermatologic

Melanoma, Neoplasm Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡